Abiopharma

🔍 Kale Jill (Executive)

Company: CELESTICA INC (CLS)

Report Date: 2026-03-31

Detailed Transactions and Holdings:

• Acquired 287 shares of Common Shares (Direct)
  Date: 2026-03-31 | Code: M | equity_swap_involved: false | shares_owned_after: 287.00 | transaction_form_type: 4
• Sold 17 shares of Common Shares at $257.27 per share (Direct)
  Date: 2026-03-31 | Code: F | equity_swap_involved: false | shares_owned_after: 270.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 287 shares of Restricted Share Units (Derivative)
  Date: 2026-03-31 | Code: M | equity_swap_involved: false | shares_owned_after: 574.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3
• Acquired 276 shares of Restricted Share Units (Derivative)
  Date: 2026-03-31 | Code: A | equity_swap_involved: false | shares_owned_after: 276.00 | transaction_form_type: 4 | Footnotes: F2, F4, F4

Footnotes:

• F1: Shares withheld to satisfy tax withholding obligations arising out of the vesting of restricted share units ("RSUs").
• F2: Each RSU represents a contingent right to receive one common share or an equivalent value in cash at the holder's election.
• F3: On March 31, 2025, the reporting person was granted 861 RSUs, 1/3 of which vest annually over 3 years on the anniversary of the grant date.
• F4: On March 31, 2026, the reporting person was granted 276 RSUs, 1/3 of which vest annually over 3 years on the anniversary of the grant date.